Inhibrx, Inc.
Anchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.
Funding history
About Inhibrx, Inc.
How much funding has Inhibrx, Inc. raised?
Inhibrx, Inc. has raised $200.0M in total funding.
Where is Inhibrx, Inc. headquartered?
Inhibrx, Inc. is headquartered in La Jolla, CA.
What does Inhibrx, Inc. do?
Anchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.
What's Inhibrx, Inc.'s solution?
Inhibrx is a clinical-stage biopharmaceutical company developing a pipeline of novel therapeutic candidates, with lead trials in sarcoma and head and neck cancer.
What makes Inhibrx, Inc. different?
They point to a proprietary single-domain antibody platform and deep protein-engineering expertise as the basis for their drug candidates.
What makes Inhibrx, Inc. notable?
Co-founded in 2010 by CEO Mark Lappe and has raised roughly $469 million, including backing from Viking Global Investors.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.